HOME >> MEDICINE >> NEWS
AMN107 has potent activity in leukemia resistant to Gleevec

The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center (meeting abstract #37).

At the 47th Annual Meeting of the American Society of Hematology (ASH), the investigators reported marked improvement in outcome in all three phases of chronic myeloid leukemia (CML) as well as benefit in treating a form of acute lymphocytic leukemia (ALL) that shares the same genetic abnormality as CML, the Philadelphia chromosome.

"This drug is very promising and appears at this point to offer an effective option for patients who do not achieve an optimal response to Gleevec therapy," says Hagop Kantarjian, M.D., professor and chair of the Department of Leukemia.

If additional studies continue to show such results, Kantarjian says, he believes AMN107, which is taken in pill form, "will either replace Gleevec as the standard of care in the future or will be used in combination with it."

Both CML and Philadelphia-positive ALL is caused by the swapping of genetic material in bone marrow stem cells between two chromosomes, which produces an abnormality called the Philadelphia chromosome. This new gene then produces a novel tyrosine kinase (Bcr-Abl) that signals the abnormal cell growth that leads to development of leukemia.

While both Gleevec and AMN107 shut down the activity of Bcr-Abl, laboratory experiments with AMN107 show it is up to 50 times more potent because it binds more efficiently to the enzyme than does Gleevec.

In the phase I clinical trial being reported, 119 patients who were resistant to Gleevec were given AMN107, and in some cases the dose was increased up to twelve fold. The researchers found that the range of response varied, depending on the form of the cancer and the presence of genetic mutations. For example, hematologic response fr
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
10-Dec-2005


Page: 1 2

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. Electric fields have potential as a cancer treatment
3. STAMP system can help professionals to identify potentially violent individuals
4. AMPAKINE compounds a new potential treatment for respiratory depression
5. Herb shows potential to reduce cancer-related fatigue
6. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
7. Women with breast cancer do not get potentially life-saving information, survey reveals
8. Eating cured meats frequently can lead to lower lung function and potential COPD
9. Clinical studies evaluate potential treatments for mouth ulcers
10. Synthetic production of potential pharmaceuticals dramatically simplified by Scripps research team
11. Obesity and environmental chemicals -- New research probes potential link

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AMN107 has potent activity leukemia resistant Gleevec

(Date:5/27/2015)... of America's most cherished actors, James Earl Jones, will ... a look at the topic of atrial fibrillation. This ... rhythm. Those who suffer from atrial fibrillation have a ... , This new segment will take a look at ... viewers about possible signs that commonly indicate the existence ...
(Date:5/27/2015)... 2015 According to research conducted by ... Center at Dallas some migraine patients have an increased ... migraine headache apparently also have some shared risk factors ... people with a history of diabetes and/or smoking. Both ... and CTS in particular was less common in Hispanics. ...
(Date:5/27/2015)... Cumming, GA (PRWEB) May 27, 2015 ... experts, traveled to six north Georgia cities on May ... as host for local physicians to meet with the ... Over 120 physicians and office staff attended. ... the event is designed to bring together Health Information ...
(Date:5/27/2015)... The Advanced Fertility Center of Chicago announces ... business to better serve the needs of couples in Chicagoland. ... on the Northwest side of the city at 4920 North ... by calling the Chicago office at (773) 794–1818. This ... of Chicago. The other 2 offices are in Gurnee ...
(Date:5/26/2015)... Phoenix, AZ (PRWEB) May 27, 2015 In ... beloved Arizona Company is offering a discount on HVAC systems ... be found here. , HVAC systems with a SEER ... some as low as $20/month. For those unfamiliar with a ... to your car. More specifically, it measures the amount of ...
Breaking Medicine News(10 mins):Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 2Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 4Health News:HomeTown Health Leads Rural Physician Bus Tour; Brings Resources and Education to North Georgia 2Health News:HomeTown Health Leads Rural Physician Bus Tour; Brings Resources and Education to North Georgia 3Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Parker and Sons Recounts its Path to Success 2
(Date:5/26/2015)... 2015 Thoratec Corporation (NASDAQ: THOR ), ... save, support and restore failing hearts, said today it ... Annual Healthcare Conference on Tuesday, June 9. ... Officer, will provide an update on the company, beginning ... Daylight Time). The presentation will be available ...
(Date:5/26/2015)... NEWARK, Calif. , May 26, 2015 Depomed, ... be presenting at two healthcare conferences in June. ... The presentation at the Jefferies conference is scheduled for 3:00 ... The 2015 JMP Securities Life Sciences Conference in ... scheduled for 11:30 am EDT (8:30 am PDT) Wednesday, June ...
(Date:5/26/2015)... --  Mallinckrodt Pharmaceuticals (NYSE: MNK ), a ... extended the deadline for submitting applications to its Research ... awards grants to help fund projects in a variety ... Awards program is designed to further scientific knowledge and ... a total of 25 positions. The program provides grants ...
Breaking Medicine Technology:Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast 2Depomed To Present At Healthcare Conferences In June 2Mallinckrodt Extends Deadline For 2015 Research Fellowship Program 2Mallinckrodt Extends Deadline For 2015 Research Fellowship Program 3
Cached News: